Hemostemix Seeks $1M Through Private Placement

Hemostemix Inc., a Calgary-based autologous stem cell therapy platform company, has announced the filing of a Form 4B to obtain price protection for the closing of the third tranche of its previously announced non-brokered private placement. The offering aims to raise $1,000,000, with each unit consisting of one common share in the capital of the Company and one-half of one common share purchase warrant. Each whole warrant entitles the holder to acquire one additional common share at a price of CDN$0.12 per share for a period of 24 months from the closing date of the third tranche of the Offering, subject to the accelerated expiry provision described in the press release.

In connection with the third tranche of the Offering, Hemostemix Inc. is expecting to pay eligible finders aggregate cash finder's fees of approximately CDN $8,000 and issue 80,000 finder warrants. Each Finder Warrant entitles the holder to purchase one common share at an exercise price of CDN$0.06 per share for a period of 24 months from the closing date of the second tranche.

The proceeds of the Offering are expected to be used for sales, marketing, patient acquisition, physician education, and commercialization initiatives; production and manufacturing expenses associated with ACP-01 treatments; regulatory and filing fees associated with submissions to the Ministry of Health and Wellness of the Commonwealth of The Bahamas; and, general working capital and corporate purposes.

The Offering remains subject to final acceptance by the TSX Venture Exchange. All securities issued in connection with the second tranche of the Offering are subject to a statutory hold period of four months plus one day from the closing date in accordance with applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.

Hemostemix Inc. is a platform company founded in 2003, a winner of the World Economic Forum Technology Pioneer Award. The company has developed and patented an investigational autologous stem cell therapy, VesCell™, derived from a patient's own blood and evaluated through structured clinical research. The company has completed seven clinical studies of 318 subjects and published its results in eleven peer-reviewed publications. ACP-01 is a safe treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. As compared to a five-year mortality rate of 50% in the CLTI diabetes-based patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result.

Hemostemix Inc. completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five-year mortality rate of 50% in the CLTI diabetes-based patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.

Hemostemix Inc. is a Calgary-based autologous stem cell therapy platform company. The company has filed a Form 4B to obtain price protection for the closing of the third tranche of its previously announced non-brokered private placement, aiming to raise $1,000,000. Each unit consists of one common share and one-half of one common share purchase warrant. The company is expecting to pay eligible finders aggregate cash finder's fees of approximately CDN $8,000 and issue 80,000 finder warrants. The proceeds of the Offering are expected to be used for sales, marketing, patient acquisition, physician education, and commercialization initiatives; production and manufacturing expenses associated with ACP-01 treatments; regulatory and filing fees associated with submissions to the Ministry of Health and Wellness of the Commonwealth of The Bahamas; and, general working capital and corporate purposes. The Offering remains subject to final acceptance by the TSX Venture Exchange. All securities issued in connection with the second tranche of the Offering are subject to a statutory hold period of four months plus one day from the closing date in accordance with applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. Hemostemix Inc. is a platform company founded in 2003, a winner of the World Economic Forum Technology Pioneer Award. The company has developed and patented an investigational autologous stem cell therapy, VesCell™, derived from a patient's own blood and evaluated through structured clinical research. The company has completed seven clinical studies of 318 subjects and published its results in eleven peer-reviewed publications. ACP-01 is a safe treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. As compared to a five-year mortality rate of 50% in the CLTI diabetes-based patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. Hemostemix Inc.